Terms: = Lymphoma AND SRC, c-SRC, 6714, ENSG00000197122, P12931, ASV, p60-Src, SRC1, c-src AND Treatment
143 results:
1. Ensartinib is effective in the treatment of advanced non-small-cell lung cancer with MET amplification after multi-line ALK-TKIs resistance: a case report.
Yang Y; He X; Xiao W; Bai J; Liu Y
Anticancer Drugs; 2024 Mar; 35(3):292-297. PubMed ID: 38179893
[TBL] [Abstract] [Full Text] [Related]
2. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract] [Full Text] [Related]
3. Novel 7-Chloro-4-aminoquinoline-benzimidazole Hybrids as Inhibitors of Cancer Cells Growth: Synthesis, Antiproliferative Activity, in Silico ADME Predictions, and Docking.
Krstulović L; Leventić M; Rastija V; Starčević K; Jirouš M; Janić I; Karnaš M; Lasić K; Bajić M; Glavaš-Obrovac L
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677600
[TBL] [Abstract] [Full Text] [Related]
4. Rhodanine Derivatives as Anticancer Agents: QSAR and Molecular Docking Studies.
Molnar M; Lončarić M; Opačak-Bernardi T; Glavaš-Obrovac L; Rastija V
Anticancer Agents Med Chem; 2023; 23(7):839-846. PubMed ID: 36305127
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of Lung Toxicity Related to the treatment With Alectinib Using a Pharmacovigilance Database.
Sato J; Uchida M; Wakabayashi H; Shimizu T
Anticancer Res; 2022 Jun; 42(6):3109-3116. PubMed ID: 35641286
[TBL] [Abstract] [Full Text] [Related]
6. A new role for the src family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.
Munshi M; Liu X; Kofides A; Tsakmaklis N; Guerrera ML; Hunter ZR; Palomba ML; Argyropoulos KV; Patterson CJ; Canning AG; Meid K; Gustine J; Branagan AR; Flynn CA; Sarosiek S; Castillo JJ; Wang J; Buhrlage SJ; Gray NS; Munshi NC; Anderson KC; Treon SP; Yang G
Blood Adv; 2022 Jun; 6(11):3332-3338. PubMed ID: 35255496
[TBL] [Abstract] [Full Text] [Related]
7. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Cordo' V; Meijer MT; Hagelaar R; de Goeij-de Haas RR; Poort VM; Henneman AA; Piersma SR; Pham TV; Oshima K; Ferrando AA; Zaman GJR; Jimenez CR; Meijerink JPP
Nat Commun; 2022 Feb; 13(1):1048. PubMed ID: 35217681
[TBL] [Abstract] [Full Text] [Related]
8. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression.
Cao X; Wang Y; Zhang W; Zhong X; Gunes EG; Dang J; Wang J; Epstein AL; Querfeld C; Sun Z; Rosen ST; Feng M
Blood; 2022 Jun; 139(22):3290-3302. PubMed ID: 35134139
[TBL] [Abstract] [Full Text] [Related]
9. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.
Leclercq G; Haegel H; Toso A; Zimmermann T; Green L; Steinhoff N; Sam J; Pulko V; Schneider A; Giusti AM; Challier J; Freimoser-Grundschober A; Larivière L; Odermatt A; Stern M; Umana P; Bacac M; Klein C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064010
[TBL] [Abstract] [Full Text] [Related]
10. Protein tyrosine phosphatase 1B(PTP1B) promotes melanoma cells progression through src activation.
Wang Q; Pan Y; Zhao L; Qi F; Liu J
Bioengineered; 2021 Dec; 12(1):8396-8406. PubMed ID: 34606417
[TBL] [Abstract] [Full Text] [Related]
11. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
[TBL] [Abstract] [Full Text] [Related]
12. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract] [Full Text] [Related]
13. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
Ran F; Liu Y; Chen X; Zhuo H; Xu C; Li Y; Duan X; Zhao G
Bioorg Chem; 2021 Jul; 112():104968. PubMed ID: 34000704
[TBL] [Abstract] [Full Text] [Related]
14. HSP90 inhibitor NVP-BEP800 affects stability of src kinases and growth of T-cell and B-cell acute lymphoblastic leukemias.
Mshaik R; Simonet J; Georgievski A; Jamal L; Bechoua S; Ballerini P; Bellaye PS; Mlamla Z; Pais de Barros JP; Geissler A; Francin PJ; Girodon F; Garrido C; Quéré R
Blood Cancer J; 2021 Mar; 11(3):61. PubMed ID: 33737511
[TBL] [Abstract] [Full Text] [Related]
15. Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Ashraf U; Ding Z; Deng S; Ye J; Cao S; Chen Z
Virulence; 2021 Dec; 12(1):968-980. PubMed ID: 33724154
[TBL] [Abstract] [Full Text] [Related]
16. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
[TBL] [Abstract] [Full Text] [Related]
17. Kinome profiling analysis identified src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract] [Full Text] [Related]
18. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.
Kawakami M; Mustachio LM; Chen Y; Chen Z; Liu X; Wei CH; Roszik J; Kittai AS; Danilov AV; Zhang X; Fang B; Wang J; Heymach JV; Tyutyunyk-Massey L; Freemantle SJ; Kurie JM; Liu X; Dmitrovsky E
Mol Cancer Ther; 2021 Mar; 20(3):477-489. PubMed ID: 33277443
[TBL] [Abstract] [Full Text] [Related]
19. Targeting N-myristoylation for therapy of B-cell lymphomas.
Beauchamp E; Yap MC; Iyer A; Perinpanayagam MA; Gamma JM; Vincent KM; Lakshmanan M; Raju A; Tergaonkar V; Tan SY; Lim ST; Dong WF; Postovit LM; Read KD; Gray DW; Wyatt PG; Mackey JR; Berthiaume LG
Nat Commun; 2020 Oct; 11(1):5348. PubMed ID: 33093447
[TBL] [Abstract] [Full Text] [Related]
20. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract] [Full Text] [Related]
[Next]
